FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to the inhibition of complement signal transmission using an anti-C5 antibody. In particular, the invention relates to methods for treating a complement-mediated disease or a complement-mediated disorder in an individual by contact between an individual and an anti-C5 antibody.
EFFECT: expansion of the range of solutions for anti-C5 antibodies.
71 cl, 45 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| ANTI-C5a ANTIBODIES AND THEIR APPLICATIONS | 2018 |
|
RU2773779C2 |
| MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3 | 2019 |
|
RU2777336C1 |
| ANTIBODIES TO S. AUREUS SURFACE DETERMINANTS | 2013 |
|
RU2698131C2 |
| ANTIBODIES TO SURFACE DETERMINANTS OF S. AUREUS | 2013 |
|
RU2808018C2 |
| EGFL6-SPECIFIC MONOCLONAL ANTIBODIES AND THEIR APPLICATION METHODS | 2017 |
|
RU2779902C2 |
| ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN AND METHODS OF THE USE THEREOF | 2015 |
|
RU2766094C2 |
| NOVEL MONOCLONAL ANTIBODIES TO LAM AND PIM6/LAM FOR DIAGNOSING AND TREATING INFECTIONS CAUSED BY MYCOBACTERIUM TUBERCULOSIS | 2017 |
|
RU2732502C2 |
| GLUCAGON RECEPTOR BINDING PROTEINS AND METHODS OF USE THEREOF | 2018 |
|
RU2820628C2 |
| TREATING CANCER USING A CHIMERIC ANTIGENIC CLL-1 RECEPTOR | 2015 |
|
RU2741120C2 |
